Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors

AIDS Reviews

Volumn 8, Issue 4, 2006, Pages 210-220

  Geretti, Anna Maria ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Fitness; Genotype; Hypersusceptibility; Phenotype; Transmission

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ARGININE; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ISOLEUCINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; LYSINE; METHIONINE; NELFINAVIR; NEVIRAPINE; PLACEBO; PROTEINASE; PROTEINASE INHIBITOR; RIBONUCLEASE H; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; UNINDEXED DRUG; VALINE; VIRUS DNA; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SENSITIVITY; DRUG TREATMENT FAILURE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONOTHERAPY; NONHUMAN; PREDICTION; PREVALENCE; REVIEW; TREATMENT OUTCOME; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 33846420173     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Svicher V, Sing T, Santoro M, et al. Involvement of novel HIV-1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 2006;80:7186-98.
2. Brehm J, Koontz D, Pathak D, Sluis-Cremer N, Mellors J. AZT selects mutations in the connection (A371V) and RNaseH (Q509L) domains of RT that increase AZT resistance in combination with TAM and reduce susceptibility to other NRTI. Program and abstracts XV International HIV Drug Resistance Workshop; June 13-17, 2006; Sitges, Spain [abstract 125].
3. Nikolenko G, Frankenberry K, Palmer S, et al. The HIV-1 reverse transcriptase connection domain from treatment-experienced patients contributes to AZT resistance. Program and abstracts XV International HIV Drug Resistance Workshop; June 13-17, 2006; Sitges, Spain [abstract 126].
4. Marcelin A, Roquebert B, Malet I, et al. Relationship between mutations in HIV-1 RNaseH domain and NRTI-resistance mutations in experienced patients. Antivir Ther 2005;10:S98.
5. Health Protection Agency. HIV Drug Resistance in the United Kingdom: data to end of 2004. CDR Weekly 2006;6:HIV/STIs.
6. Garcia-Leon M, de Mendoza C, Corral A, Gonzales-Lahoz J, Soriano V. Evolution of drug-resistance mutations in antiretroviral-experienced individuals seen between 1999-2005. Program and abstracts 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Monaco [abstract 15].
7. Van de Vijver D, Wensing A, Asjo B, et al. Patterns of predicted drug susceptibility and its change over time among 2000 isolates across Europe: the CAPTURE study. Program and abstracts 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Monaco [abstract 4].
8. McColl D, Parkin N, Miller M. Characterization of patient-derived HIV-1 isolates containing the L74V or K65R mutations in reverse transcriptase. Program and abstracts 44th ICAAC. October 30-November 2, 2004; Washington, DC [abstract H-178].
9. Corvasce S, Violin M, Romano L, et al. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters. Antivir Ther 2006;11:329-34.
10. Booth L, Garcia-Diaz A, Nebbia G, Youle M, Johnson M, Geretti A. The prevalence of antiretroviral drug resistance in patients with low-level detectable viremia while on HAART. Antivir Ther 2006;11:S130.
11. Geretti A. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007 (in press).
12. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr 2006;41:439-46.
13. Booth C, Garcia-Diaz A, Youle M, Johnson M, Phillips A, Geretti A. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother (in press).
14. Oette M, Kaiser R, Daumer M, et al. Primary HIV drug resistance and efficacy of first-line antiretroviral therapy guided by resistance testing. J Acquir Immune Defic Syndr 2006;41:573-81.
15. Maia Teixeira S, Bastos F, Hacker M, et al. Trends in drug-resistance mutations in antiretroviral-naive intravenous drug users of Rio de Janeiro. J Med Virol 2006;78:764-9.
16. Bezemer D, de Ronde A, Prins M, et al. Evolution of transmitted HIV-1 with drug-resistance mutations in the absence of therapy: effects on CD4+ T-cell count and HIV-1 RNA load. Antivir Ther 2006;11:173-8.
17. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20:159-70.
18. Gallant J, Pozniak A, DeJesus E, et al. Efficacy and safety of tenofovir DF (TDF), emtricitabine (FTC) and efavirenz (EFV) compared to fixed dose zidovudine/lamivudine (CBV) and EFV through 96 weeks in antiretroviral treatment-naive patients. Program and abstracts XVI International AIDS Conference. August 13-18, 2006; Toronto, Canada [abstract TUPE0064].
19. Miller M, Margot N, McColl D, Tran S, Coakley D, Cheng A. Genotypic and phenotypic characterization of virologic failure through 48 weeks among treatment-naive patients taking tenofovir DF or stavudine in combination with lamivudine and efavirenz. Program and abstracts 6th International Congress on Drug Therapy in HIV infection. November 17-21, 2002; Glasgow, UK [abstract P205].
20. Molina J, Wilkin A, Domingo P, et al. Once-daily vs. twice-daily lopinavir/ritonavir in antiretroviral-naive patients: 96-week results. Program and abstracts 3rd IAS Conference on HIV Pathogenesis and Treatment, July 24-27, 2005; Rio de Janeiro, Brazil [abstract WePe12.3C12].
21. Dejesus E, Herrera G, Teofilo E, et al. Efficacy and safety of abacavir versus zidovudine in antiretroviral therapy-naive adults with HIV-1 infection (Study CNA30024). Program and abstracts 43rd ICAAC. September 14-17, 2003; Chicago, IL [abstract H-446].
22. Gazzard B, DeJesus E, Cahn P, et al. Abacavir once daily plus lamivudine once daily in combination with efavirenz once daily is well-tolerated and effective in the treatment of antiretroviral therapy naive adults with HIV-1 infection (ZODIAC Study: CNA30021). Program and abstracts 43rd ICAAC. September 14-17, 2003: Chicago, IL [abstract H-1722b].
23. MacManus S, Yates P, Elston R, White S, Richards N, Snowden W. GW433908/ ritonavir once daily in antiretroviral therapy naive HIV-infected patients: absence of protease resistance at 48 weeks. AIDS 2004;18:651-5.
24. Zurita Macias Valadez L, Rodriguez-Diaz R, Fuentes-Romero L, Andrade-Toscano E, Soto-Ramirez L. Development of TAM after failure of first ARV treatment in Mexico. Program and abstracts 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Monaco [abstract 45].
25. Kempf D, King M, Bernstein B, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189:51-60.
26. Hicks C, King M, Gulick R, White A, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 2004;18:775-9.
27. Malan N, Krantz E, David N, et al. Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089. Program and abstracts 13th CROI; February 5-8, 2006; Denver, CO [abstract 107LB].
28. Van Houtte M, Staes M, Geretti A, Pattery T, Bacheler L. Tenofovir drug resistance and mutational pathways associated with the RT mutation K70E in HIV-1. Program and abstracts 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Monaco [abstract 94].
29. Stone C, Craig C. Identification of a new HIV-1 in vitro mutation to tenofovir and mutation patterns observed to the drug combinations abacavir/tenofovir/3TC, abacavir/3TC and tenofovir/FTC. Program and abstracts 3rd European HIV Drug Resistance Workshop; March 30-April 1, 2005; Athens, Greece [abstract 98].
30. Murry J, Higgins J, Matthews T, et al. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol 2003;77:1120-30.
31. Marcelin A, Flandre P, Pavie J, et al. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob Agents Chemother 2005;49:1739-44.
32. Waters J, Margot N, McColl D, Zhong L, Miller M. K65R, L74V and thymidine analog mutations in HIV-1 RT associated with reduced response to tenofovir DF in ART-experienced patients. Program and abstracts 13th CROI; February 5-8, 2006; Denver, CO [abstract 633].
33. Stone C, Lanier E, Craig C. In vitro selection of a novel reverse transcriptase mutation, D67H, by tenofovir/zidovudine in wild-type virus and of D67N/H by TFV alone in a background of thymidine analog mutations. Program and abstracts 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Monaco [abstract 98].
34. Wainberg M. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev Anti Infect Ther 2004;2:147-51.
35. Diallo K, Gotte M, Weinberg M. Molecular impact of the M184V mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother 2003;47:3377-83.
36. Liang F, Miranda L, Kuritzkes D. The Impact of the M184V substitution in HIV-1 reverse transcriptase on DNA 3′-end and RNA 5′-end-directed ribonuclease H (RNaseH) activity. Program and abstracts 13th CROI; February 5-8, 2006; Denver, CO [abstract 600].
37. 3. N Engl J Med 1995;333:1662-9.
38. The CAESAR Trial Study Group. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997;349:1413-21.
39. Castagna A, Danise A, Menzo S, et al. Lamivudine monotherapy in HIV-1-infected patients harboring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 2006;20:795-803.
40. Ledergerber B, Lundgren J, Walker A, et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virologic failure to all three antiretroviral-drug classes. Lancet 2004;364:51-62.
41. Deeks S, Hoh R, Neilands T, et al. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J Infect Dis 2005;192:1537-44.
42. Deeks S, Lu J, Hoh R, et al. Interruption of enfuvirtide in patients with enfuvirtide resistance. Program and abstracts 12th CROI; February 22-25, 2005; Boston, MA [abstract 680].
43. Geretti A, Sabin C, Dunn D. The H208Y mutation in reverse transcriptase is significantly associated with NRTI exposure, M184V and TAM mutation pathways. Antivir Ther 2006;11:S158.
44. Ross L, Parkin N, Gerondelis P, et al. Differential impact of thymidine analog mutations on emtricitabine and lamivudine susceptibility. J Acquir Immune Defic Syndr 2006;43:567-70.
45. Garcia-Lerma J, MacInnes H, Bennett D. A novel genetic pathway of HIV-1 resistance to stavudine mediated by the K65R mutation. J Virol 2003;77:5685-93.
46. Parikh U, Bacheler L, Koontz D, Mellors J. The K65R mutation in HIV-1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol 2006; 80:4971-7.
47. White K, Chen J, Feng J, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006;11:155-63.
48. White K, Margot N, Ly J, et al. A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT. AIDS 2005;19:1751-60.
49. Staszewski S, Dauer B, Locher L, Moesch M, Gute P, Stuermer M. Intensification of a failing regimen with zidovudine may cause sustained virologic suppression in the presence of the K65R mutation. Program and abstracts 13th CROI; February 5-8, 2006; Denver, CO [abstract 635].
50. DART Virology Group and Trial Team. Virologic response to a triple nucleoside/nucleotide analog regimen over 48 weeks in HIV-1-infected adults in Africa. AIDS 2006;20:1391-9.
51. Frankel F, Marchand B, Turner D, Gotte M, Wainberg M. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother 2005;49:2657-64.
52. Miranda L, Gotte M, Liang F, Kuritzkes D. The L74V mutation in HIV-1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005;49: 2648-56.
53. Wirden M, Roquebert B, Derache A, et al. Risk factors for selection of the L74I reverse transcriptase mutation in HIV-1-infected patients. Antimicrob Agents Chemother 2006;50:2553-6.
54. http://www.vircolab.com/bgdisplay.jhtml?itemname= vircotype_ccoffs&product=vircotype [accessed 03/ 12/2006].
55. http://www.monogramhiv.com/assays/hcp/phenoGTReport.aspx [accessed 03/12/ 2006].
56. Underwood M, St Clair M, Ross L, Gerondelis P, Parkin N, Lanier R. Cross-resistance of Clinical Samples with K65R, L74V, and M184V Mutations. Program and abstracts 12th CROI; February 22-25, 2005; Boston, MA [abstract 714].
57. Violin M, Cozzi-Lepri A, Velleca R, et al. Risk of failure of patients with 215 HIV-1 revertants starting their first thymidine analog-containing HAART. AIDS 2004;18:227-35.
58. Masquelier B, Tamalet C, Montes B, et al. Genotypic determinants of the virologic response to tenofovir disoproxil fumarate in NRTI-experienced patients. Antivir Ther 2004;9:315-23.
59. Trivedi V, Han X, Montes-Walters M, Filizzola M, Ferguson M, O'Brien W. Effect of L74V or M184V, with multiple thymidine analog-associated mutations, on reverse transcriptase inhibitor phenotypic sensitivity. Program and abstracts 12th CROI; February 22-25, 2005; Boston, MA [abstract 703].
60. Svarovoskaia E, Margot N, Bae A, Waters J, Borroto-Esoda K, Miller M. Allele-specific PCR shows low-level K65R in treatment experienced patients with L74V in the absence of TAM. Antivir Ther 2006;11:S80.
61. Descamps D, Delarue S, Ait-Khaled M, Craig C, Collin G, Brun-Vézinet F. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/lamivudine containing HAART regimen. Program and abstracts 4th European HIV Drug Resistance Workshop; March 29-31, 2006; Monte Carlo, Monaco [abstract 64].